Acloproxalap is under clinical development by Aldeyra Therapeutics and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome. According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Acloproxalap LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Acloproxalap overview
Acloproxalap (ADX-629) is under development for the treatment of plaque psoriasis, atopic (allergic) asthma, obesity, acute alcoholic hepatitis, cytokine storm, ethanol toxicity, minimal change disease, atopic dermatitis and Sjogren-Larsson syndrome and COVID-19. The drug candidate is RASP (Reactive Aldehydes Species-Pro-inflammatory) inhibitor, administered through oral route. It is an analog of reproxalap. It acts by targeting aldehyde load.
It was under development for nephrotic syndrome, non-alcoholic steatohepatitis (NASH), chronic cough and inflammatory bowel disease (IBD).
Aldeyra Therapeutics overview
Aldeyra Therapeutics is a biotechnology company that discover and develops therapies for the treatment of immune-mediated and metabolic diseases. The company pipeline products include Reproxalap, ADX-629, ADX-248, ADX-743, ADX-631, and ADX-2191 for various indications comprise dry eye disease, allergic conjunctivitis, moderate alcoholic hepatitis, Sjogren Larsson syndrome, atopic dermatitis, obesity and hypertriglyceridemia, dry age-related macular degeneration, geographical atrophy, retinitis pigmentosa and retinitis pigmentosa. The company also utilizes RASP (reactive aldehyde species) modulator platform . It operates in Germany and the US. Aldeyra Therapeutics is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Acloproxalap’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
